UK health regulator -- UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) – has continued the approval status of Wockhardt’s manufacturing unit at Kadaiya, Daman relating to the principles and guidelines of Good Manufacturing Practices (GMP). The said manufacturing unit complies with the principles and guidelines which has now been continued by UK MHRA.
Last month, the company’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, had been issued a Warning Letter by the US Food and Drug Administration (USFDA).
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
